Market Cap | 86.90M | P/E | 36.25 | EPS this Y | 30.60% | Ern Qtrly Grth | 71.30% |
Income | 3.94M | Forward P/E | 16.92 | EPS next Y | - | 50D Avg Chg | -10.00% |
Sales | 51.69M | PEG | 2.53 | EPS past 5Y | -4.55% | 200D Avg Chg | -7.00% |
Dividend | N/A | Price/Book | 2.39 | EPS next 5Y | 15.00% | 52W High Chg | -27.00% |
Recommedations | 2.00 | Quick Ratio | 5.17 | Shares Outstanding | 8.61M | 52W Low Chg | 11.00% |
Insider Own | 26.70% | ROA | 7.21% | Shares Float | 5.88M | Beta | 0.42 |
Inst Own | 32.73% | ROE | 10.40% | Shares Shorted/Prior | 36.41K/52.55K | Price | 10.15 |
Gross Margin | 76.51% | Profit Margin | 7.62% | Avg. Volume | 9,516 | Target Price | - |
Oper. Margin | 16.53% | Earnings Date | May 7 | Volume | 1,516 | Change | 0.00% |
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care and institutional markets for patients with bronchiectasis, cystic fibrosis, and neuromuscular diseases. It markets its products primarily to physicians and health care providers, as well as directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
EF Hutton | Buy | May 11, 23 |
EF Hutton | Buy | Feb 16, 23 |
Lake Street | Buy | Feb 15, 23 |
EF Hutton | Buy | Sep 6, 22 |
Lake Street | Buy | Aug 5, 22 |
Northland Capital Markets | Outperform | Nov 24, 20 |
Dougherty & Co. | Buy | Oct 18, 19 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Summers Andrew | Director Director | Dec 14 | Buy | 10.50 | 28,797 | 302,368 | 351,921 | 12/18/23 |
SKARVAN KATHLEEN | President and CEO President and CEO | Feb 27 | Option | 1.36 | 65,000 | 88,400 | 208,556 | 03/06/23 |
SKARVAN KATHLEEN | President and CEO President and CEO | Sep 12 | Option | 1.75 | 20,000 | 35,000 | 163,556 | 09/14/22 |